R 115866: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
talarozole : A racemate comprising equimolar amounts of (R)- and (S)-talarozole. It is used for the treatment of keratinization disorders, psoriasis and acne. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
N-{4-[2-ethyl-1-(1,2,4-triazol-1-yl)butyl]phenyl}-1,3-benzothiazol-2-amine : A member of the class of benzothiazoles that is 2-amino-1,3-benzothiazole in which one of the amino hydrogens is replaced by a 4-[2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl]phenyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 9799888 |
| CHEMBL ID | 459505 |
| CHEBI ID | 102167 |
| SCHEMBL ID | 721201 |
| SCHEMBL ID | 21020998 |
| MeSH ID | M0360638 |
| Synonym |
|---|
| talarozole |
| r-115866 |
| rambazole |
| r115866 , |
| n-(4-(2-ethyl-1-(1h-1,2,4-triazol-1-yl)butyl)phenyl)-2-benzothiazolamine |
| r 115866 |
| bdbm50253810 |
| n-(4-(2-ethyl-1-(1h-1,2,4-triazol-1-yl)butyl)phenyl)benzo[d]thiazol-2-amine |
| 201410-53-9 |
| D09385 |
| rambazole (tn) |
| talarozole (usan/inn) |
| CHEMBL459505 , |
| AKOS005067289 |
| CHEBI:102167 |
| n-{4-[2-ethyl-1-(1h-1,2,4-triazol-1-yl)butyl]phenyl}-1,3-benzothiazol-2-amine |
| n-{4-[2-ethyl-1-(1,2,4-triazol-1-yl)butyl]phenyl}-1,3-benzothiazol-2-amine |
| 2-benzothiazolamine, n-(4-(2-ethyl-1-(1h-1,2,4-triazol-1-yl)butyl)phenyl)- |
| unii-xkd9n5cj6w |
| talarozole [usan:inn] |
| xkd9n5cj6w , |
| n-(4-((1rs)-2-ethyl-1-(1h-1,2,4-triazol-1-yl)butyl)phenyl)benzothiazol-2-amine |
| HY-14531 |
| CS-1343 |
| SCHEMBL721201 |
| talarozole [who-dd] |
| n-[4-[(1rs)-2-ethyl-1-(1h-1,2,4-triazol-1-yl)butyl]phenyl]benzothiazol-2-amine |
| talarozole [usan] |
| 851811-31-9 |
| talarozole [inn] |
| (+/-)-n-[4-[2-ethyl-1-(1h-1,2,4-triazol-1-yl)butyl]phenyl]-2-benzothiazol-amine |
| (+/-)-n-[4-[2-ethyl-1-(1h-1,2,4-triazol-1-yl)butyl]phenyl]-2-benzothiazolamine |
| SNFYYXUGUBUECJ-UHFFFAOYSA-N |
| SCHEMBL21020998 |
| NCGC00378894-01 |
| DB13083 |
| (+)-talarozole |
| BCP21218 |
| talarozole r enantiomer;r115866;r 115866;r-115866 |
| DTXSID70942185 |
| BCP28256 |
| rambazole; r115866; r-115866; r 115866 |
| Q15410180 |
| (+)-n-[4-[2-ethyl-1-(1h-1,2,4-triazol-1-yl)butyl]phenyl]-2-benzothiazolamine |
| 201410-66-4 |
| n-[4-[2-ethyl-1-(1,2,4-triazol-1-yl)butyl]phenyl]-1,3-benzothiazol-2-amine |
| 2-benzothiazolamine, n-[4-[2-ethyl-1-(1h-1,2,4-triazol-1-yl)butyl]phenyl]- |
| D85497 |
| n-{4-[2-ethyl-1-(1h-1,2,4-triazol-1-yl)butyl]phenyl}-1,3-benzothi azol-2-amine |
| A926099 |
| WS-02133 |
| gtpl11381 |
| NCGC00378894-02 |
| BIA41053 |
| Z2037280125 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " However, no local pharmacokinetic data on the diffusion behaviour of talarozole in the skin itself are available." | ( Local skin pharmacokinetics of talarozole, a new retinoic acid metabolism-blocking agent. Baert, B; De Spiegeleer, B, 2011) | 0.37 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The objective of the study was to investigate the regulation of meiosis-associated and male germ cell-related genes, stimulated by retinoic acid gene 8 (STRA8), synaptonemal complex protein 3 (SYCP3), dosage suppressor of mck1 (DMC1), doublesex and mab-3 related transcription factor 1 (DMRT1) and deleted in azoospermia-like (DAZL) following exogenous administration of retinoic acid (RA) and after the modulation of endogenous RA by a cytochrome P450, family 26, subfamily B, polypeptide 1 inhibitor (CYP26B1-I; R115866) in an in vitro testis model." | ( Exogenous retinoic acid and cytochrome P450 26B1 inhibitor modulate meiosis-associated genes expression in canine testis, an in vitro model. Kasimanickam, R; Kasimanickam, V, 2014) | 0.4 |
| Class | Description |
|---|---|
| triazoles | An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms. |
| benzothiazoles | |
| aromatic amine | An amino compound in which the amino group is linked directly to an aromatic system. |
| secondary amino compound | A compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| PPM1D protein | Homo sapiens (human) | Potency | 29.4107 | 0.0052 | 9.4661 | 32.9993 | AID1347411 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 0.2684 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
| G | Vesicular stomatitis virus | Potency | 0.9522 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 2.3919 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
| Interferon beta | Homo sapiens (human) | Potency | 22.2961 | 0.0033 | 9.1582 | 39.8107 | AID1347411; AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 0.9522 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 0.9522 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 0.9522 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cytochrome P450 26A1 | Homo sapiens (human) | IC50 (µMol) | 0.0051 | 0.0051 | 3.4125 | 7.8000 | AID1290556 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 (µMol) | 0.0005 | 0.0001 | 1.7536 | 10.0000 | AID1290555 |
| Cytochrome P450 26B1 | Homo sapiens (human) | IC50 (µMol) | 0.0005 | 0.0005 | 1.9728 | 5.9000 | AID1290555 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cytochrome P450 26A1 | Homo sapiens (human) | EC50 (µMol) | 0.0050 | 0.0050 | 3.5025 | 7.0000 | AID1799732 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1290556 | Inhibition of microsomal fraction of human CYP26A1 expressed in Sf9 cells using 9-cis-RA as substrate preincubated for 5 mins followed by NADPH addition measured after 1 min by HPLC analysis in presence of rat P450 reductase | 2016 | Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6 | Development and Characterization of Novel and Selective Inhibitors of Cytochrome P450 CYP26A1, the Human Liver Retinoic Acid Hydroxylase. |
| AID1290555 | Inhibition of microsomal fraction of human CYP26B1 expressed in Sf9 cells using 9-cis-RA as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by HPLC analysis in presence of rat P450 reductase | 2016 | Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6 | Development and Characterization of Novel and Selective Inhibitors of Cytochrome P450 CYP26A1, the Human Liver Retinoic Acid Hydroxylase. |
| AID1799732 | Cell Assay from Article 10.1080/14756360802218334: \\Design and synthesis of substituted imidazole and triazole N-phenylbenzo[d]oxazolamine inhibitors of retinoic acid metabolizing enzyme CYP26.\\ | 2009 | Journal of enzyme inhibition and medicinal chemistry, Apr, Volume: 24, Issue:2 | Design and synthesis of substituted imidazole and triazole N-phenylbenzo[d]oxazolamine inhibitors of retinoic acid metabolizing enzyme CYP26. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (43.75) | 29.6817 |
| 2010's | 13 (40.63) | 24.3611 |
| 2020's | 5 (15.63) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.11) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (9.38%) | 5.53% |
| Reviews | 2 (6.25%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 27 (84.38%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label, Multi-Center Pilot Trial to Assess the Efficacy and Safety of Oral R115866 in the Treatment of Subjects With Moderate to Severe Plaque Type Psoriasis [NCT00725348] | Phase 2 | 19 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Placebo-Controlled, Investigator Blinded, Explorative Trial to Evaluate the Anti-inflammatory Effect of Multiple Topical Applications of R115866 Gel (0.35%) in Two Models of Cutaneous Inflammation in Healthy Male Subjects [NCT00719121] | Phase 1 | 12 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| An Open Label Pilot Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment of Moderate to Severe Facial Acne [NCT00725439] | Phase 2 | 16 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| A Randomized, Evaluator-Blind, Placebo-Controlled, Parallel-Group Dose-Ranging Study of the Safety and Efficacy of Oral R115866 and R115866 Placebo in the Treatment of Plaque Psoriasis [NCT00716144] | Phase 2 | 176 participants (Actual) | Interventional | 2006-06-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||